The effect of hematopoietic stem cell transplantation on fertility and strategies for improvement.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
11
05
2022
accepted:
15
08
2022
revised:
30
07
2022
pubmed:
30
8
2022
medline:
5
11
2022
entrez:
29
8
2022
Statut:
ppublish
Résumé
Ovarian dysfunction is an important consequence of hematopoietic stem cell transplantation (HCT). Premature ovarian failure and infertility can severely impact the quality of life for the increasing number of female long-term survivors of HCT. Here, we review the impact of HCT on ovarian function, post-transplant fertility and birth outcomes, and the contemporaneous strategies to preserve fertility for these patients.
Identifiants
pubmed: 36038764
doi: 10.1038/s41409-022-01792-6
pii: 10.1038/s41409-022-01792-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1649-1656Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Phelan R, Arora M, Chen M Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR US Summary Slides.; 2020.
Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2. https://doi.org/10.1016/S2352-3026(15)00028-9
Donnez J, Squifflet J, Jadoul P, Demylle D, Cheron AC, Van Langendonckt A, et al. Pregnancy and live birth after autotransplantation of frozen-thawed ovarian tissue in a patient with metastatic disease undergoing chemotherapy and hematopoietic stem cell transplantation. Fertil Steril. 2011;95. https://doi.org/10.1016/j.fertnstert.2010.11.041
Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87. https://doi.org/10.1182/blood.v87.7.3045.bloodjournal8773045
Carter A, Robison LL, Francisco L, Smith D, Grant M, Baker KS, et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: Report from the bone marrow transplant survivor study. Bone Marrow Transpl. 2006;37. https://doi.org/10.1038/sj.bmt.1705364
Loren AW, Chow E, Jacobsohn DA, Gilleece M, Halter J, Joshi S, et al. Pregnancy after Hematopoietic Cell Transplantation: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transpl. 2011;17:157–66. https://doi.org/10.1016/j.bbmt.2010.07.009
doi: 10.1016/j.bbmt.2010.07.009
Wallace WHB, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5:e8772 https://doi.org/10.1371/journal.pone.0008772
doi: 10.1371/journal.pone.0008772
pubmed: 20111701
pmcid: 2811725
Stroud JS, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW. Effects of cancer treatment on ovarian function. Fertil Steril. 2009;92:417–427. https://doi.org/10.1016/j.fertnstert.2008.07.1714
doi: 10.1016/j.fertnstert.2008.07.1714
pubmed: 18774559
Joshi S, Savani BN, Chow EJ, Gilleece MH, Halter J, Jacobsohn DA, et al. Clinical guide to fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transpl. 2014;49:477–84. https://doi.org/10.1038/bmt.2013.211
doi: 10.1038/bmt.2013.211
Sanders JE, Buckner CD, Amos D, Levy W, Appelbaum FR, Doney K, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol. 1988;6:813–818. https://doi.org/10.1200/JCO.1988.6.5.813
doi: 10.1200/JCO.1988.6.5.813
pubmed: 3130466
Somali M, Mpatakoias V, Avramides A, Sakellari I, Kaloyannidis P, Smias C, et al. Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases. Gynecol Endocrinol. 2005;21:18–26. https://doi.org/10.1080/09513590500099255
doi: 10.1080/09513590500099255
pubmed: 16048797
Mertens AC, Ramsay NKC, Kouris S, Neglia JP. Patterns of gonadal dysfunction following bone marrow transplantation. Bone Marrow Transpl. 1998;22:345–50. https://doi.org/10.1038/sj.bmt.1701342
doi: 10.1038/sj.bmt.1701342
Phelan R, Mann E, Napurski C, Defor TE, Petryk A, Miller WP, et al. Ovarian function after hematopoietic cell transplantation: A descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning. Bone Marrow Transpl. 2016;51:1369–1375. https://doi.org/10.1038/bmt.2016.150
doi: 10.1038/bmt.2016.150
Ashizawa M, Akahoshi Y, Nakano H, Kawamura S, Takeshita J, Yoshino N, et al. Updated clinical outcomes of hematopoietic stem cell transplantation using myeloablative total body irradiation with ovarian shielding to preserve fertility. Biol Blood Marrow Transpl. 2019;25:2461–2467. https://doi.org/10.1016/j.bbmt.2019.07.039
doi: 10.1016/j.bbmt.2019.07.039
Socié G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101:3373–85. https://doi.org/10.1182/blood-2002-07-2231
doi: 10.1182/blood-2002-07-2231
pubmed: 12511420
Shanis D, Merideth M, Klepac Pulanic T, Savani BN, Battiwalla M, Stratton P, Female long term survivors after allo-HSCT: evaluation and management. Semin Hematol. 2012;49:83–93.
doi: 10.1053/j.seminhematol.2011.10.002
pubmed: 22221788
pmcid: 3257831
Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: High-dose busulfan is a major cause of ovarian failure. Bone Marrow Transpl. 1998;22:989–994. https://doi.org/10.1038/sj.bmt.1701483
doi: 10.1038/sj.bmt.1701483
Jadoul P, Anckaert E, Dewandeleer A, Steffens M, Dolmans MM, Vermylen C, et al. Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence. Fertil Steril. 2011;96:126–133.e3. https://doi.org/10.1016/j.fertnstert.2011.03.108
doi: 10.1016/j.fertnstert.2011.03.108
pubmed: 21550046
Maeda N, Kato K, Matsuyama T, Kojima S, Ohyama K. High-dose busulfan is a major risk factor for ovarian dysfunction in girls after stem cell transplantation. Clin Pediatr Endocrinol. 2003;12:13–18. https://doi.org/10.1297/cpe.12.13
doi: 10.1297/cpe.12.13
Salooja N, Szydlo RM, Socie G, Rio B, Chatterjee R, Ljungman P, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: A retrospective survey. Lancet 2001;358:271–6. https://doi.org/10.1016/S0140-6736(01)05482-4
doi: 10.1016/S0140-6736(01)05482-4
pubmed: 11498213
Chatterjee R, Mills W, Katz M, McGarrigle HH, Goldstone AH, Prospective study of pituitary-gonadal function to evaluate short-term effects of ablative chemotherapy or total body irradiation with autologous or allogenic marrow transplantation in post-menarcheal female patients. Bone Marrow Transpl. 1994;13:511–7.
Schimmer AD, Quatermain M, Imrie K, Ali V, McCrae J, Stewart AK, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol. 1998;16:2359–63. https://doi.org/10.1200/JCO.1998.16.7.2359
doi: 10.1200/JCO.1998.16.7.2359
pubmed: 9667251
Cheng YC, Saliba RM, Rondón G, Giralt SA, Lu KH, Bodurka DC, et al. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica. 2005;90:1725–6.
pubmed: 16330461
Kawano M, Komura H, Kawaguchi H, Shimizu S, Yada-Hashimoto N, Shimizu M, et al. Ovarian insufficiency following allogeneic hematopoietic stem cell transplantation. Gynecol Endocrinol. 2017;33:156–159. https://doi.org/10.1080/09513590.2016.1230193
doi: 10.1080/09513590.2016.1230193
pubmed: 27808585
Toro HO, del, Howell JC, Badia P, Benoit J, Davies SM, Grimley MS, et al. Reduced fertility potential in young patients following hematopoietic stem cell transplantation despite reduced-intensity conditioning. Biol Blood Marrow Transpl. 2018;24:S89–S90. https://doi.org/10.1016/j.bbmt.2017.12.672
doi: 10.1016/j.bbmt.2017.12.672
Forgeard N, Jestin M, Vexiau D, Chevillon F, Ricadat E, Peffault de Latour R, et al. Sexuality- and fertility-related issues in women after allogeneic hematopoietic stem cell transplantation. Transpl Cell Ther. 2021;27:432.e1–432.e6. https://doi.org/10.1016/j.jtct.2021.02.003
doi: 10.1016/j.jtct.2021.02.003
Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102:614–625. https://doi.org/10.3324/haematol.2016.150250
doi: 10.3324/haematol.2016.150250
pubmed: 28232372
pmcid: 5395102
Mosher CE, Duhamel KN, Rini C, Corner G, Lam J, Redd WH. Quality of life concerns and depression among hematopoietic stem cell transplant survivors. Support Care Cancer. 2011;19:1357–65. https://doi.org/10.1007/s00520-010-0958-y
doi: 10.1007/s00520-010-0958-y
pubmed: 20661753
Claessens JJM, Beerendonk CCM, Schattenberg AVMB. Quality of life, reproduction, and sexuality after stem cell transplantation with partially T-cell-depleted grafts and after conditioning with a regimen including total body irradiation. Bone Marrow Transpl. 2006;37:831–836. https://doi.org/10.1038/sj.bmt.1705350
doi: 10.1038/sj.bmt.1705350
Chiodi S, Spinelli S, Ravera G, Petti AR, Van Lint MT, Lamparelli T, et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol. 2000;110:614–9. https://doi.org/10.1046/j.1365-2141.2000.02053.x
doi: 10.1046/j.1365-2141.2000.02053.x
pubmed: 10997973
Syrjala KL, Schoemans H, Yi JC, Langer SL, Mukherjee A, Onstad L, et al. Sexual functioning in long-term survivors of hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020;27:80.e1–80.e12. https://doi.org/10.1016/j.bbmt.2020.09.027 . Published online
doi: 10.1016/j.bbmt.2020.09.027
Syrjala KL, Kurland BF, Abrams JR, Sanders JE, Heiman JR. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood. 2008;111:989–996. https://doi.org/10.1182/blood-2007-06-096594
doi: 10.1182/blood-2007-06-096594
pubmed: 17878404
pmcid: 2214742
Machado AMN, Hamerschlak N, Rodrigues M, Piccinato C de A, Podgaec S, et al. Female genital tract chronic graft-versus-host disease: A narrative review. Hematol Transfus Cell Ther. 2019;41. https://doi.org/10.1016/j.htct.2018.06.005
Spinelli S, Chiodi S, Costantini S, Van Lint MT, Raiola AM, Ravera G, et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 2003;88:1163–8.
pubmed: 14555313
Hamilton BK, Goje O, Savani BN, Majhail NS, Stratton P. Clinical management of genital chronic GvHD. Bone Marrow Transpl. 2017;52:803–810. https://doi.org/10.1038/bmt.2016.315
doi: 10.1038/bmt.2016.315
Spiryda LB, Laufer MR, Soiffer RJ, Antin JA. Graft-versus-host disease of the vulva and/or vagina: Diagnosis and treatment. Biol Blood Marrow Transpl. 2003;9:760–765. https://doi.org/10.1016/j.bbmt.2003.08.001
doi: 10.1016/j.bbmt.2003.08.001
Shimoji S, Hashimoto D, Kato K, Tujigiwa H, Akashi K, Teshima T. Graft-versus-host disease targets granulosa cell of ovarian follicle and causes infertility after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21:S26–S27. https://doi.org/10.1016/j.bbmt.2014.11.014
doi: 10.1016/j.bbmt.2014.11.014
Shimoji S, Hashimoto D, Tsujigiwa H, Miyawaki K, Kato K, Takahashi S, et al. Graft-versus-host disease targets ovary and causes female infertility in mice. Blood. 2017;129:1216–1225. https://doi.org/10.1182/blood-2016-07-728337
doi: 10.1182/blood-2016-07-728337
pubmed: 27903524
Borgmann-Staudt A, Rendtorff R, Reinmuth S, Hohmann C, Keil T, Schuster FR, et al. Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence. Bone Marrow Transpl. 2012;47:271–6. https://doi.org/10.1038/bmt.2011.78
doi: 10.1038/bmt.2011.78
Gerstl B, Sullivan E, Koch J, Wand H, Ives A, Mitchell R, et al. Reproductive outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors: a systematic review and meta-analysis. Support Care Cancer. 2019;27:4451–4460. https://doi.org/10.1007/s00520-019-05020-8
doi: 10.1007/s00520-019-05020-8
pubmed: 31541306
Diesch-Furlanetto T, Rovó A, Galimard JE, Szinnai G, Dalissier A, Sedlacek P, et al. Pregnancy and pregnancy outcomes after hematopoietic stem cell transplantation in childhood: A cross-sectional survey of the EBMT Pediatric Diseases Working Party. Hum Reprod. 2021;36:2871–2882. https://doi.org/10.1093/humrep/deab199
doi: 10.1093/humrep/deab199
pubmed: 34529796
Tichelli A, Rovó A. Fertility issues following hematopoietic stem cell transplantation. Expert Rev Hematol. 2013;6:375–88. https://doi.org/10.1586/17474086.2013.816507
doi: 10.1586/17474086.2013.816507
pubmed: 23991924
Ozdemir ZN, Bozdag SC. Hematological malignancies and fertility. Adv Exp Med Biol. 2020;1288:103–115. https://doi.org/10.1007/5584_2020_490
doi: 10.1007/5584_2020_490
pubmed: 32124411
Loren AW, Brazauskas R, Chow EJ, Gilleece M, Halter J, Jacobsohn DA, et al. Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transpl. 2013;48:1091–7. https://doi.org/10.1038/bmt.2013.13
doi: 10.1038/bmt.2013.13
Lawrenz B, Jauckus J, Kupka M, Strowitzki T, Von Wolff M. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril. 2010;94:2871–3. https://doi.org/10.1016/j.fertnstert.2010.06.054
doi: 10.1016/j.fertnstert.2010.06.054
pubmed: 20678763
Balduzzi A, Dalle JH, Jahnukainen K, Von Wolff M, Lucchini G, Ifversen M, et al. Fertility preservation issues in pediatric hematopoietic stem cell transplantation: Practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group. Bone Marrow Transpl. 2017;52:1406–1415. https://doi.org/10.1038/bmt.2017.147
doi: 10.1038/bmt.2017.147
Tao T, Del Valle A. Human oocyte and ovarian tissue cryopreservation and its application. J Assist Reprod Genet. 2008;25:287–96. https://doi.org/10.1007/s10815-008-9236-z
doi: 10.1007/s10815-008-9236-z
pubmed: 18670872
pmcid: 2596676
Chung EH, Lim SL, Myers E, Moss HA, Acharya KS. Oocyte cryopreservation versus ovarian tissue cryopreservation for adult female oncofertility patients: a cost-effectiveness study. J Assist Reprod Genet. 2021;38:2435–2443. https://doi.org/10.1007/s10815-021-02222-0
doi: 10.1007/s10815-021-02222-0
pubmed: 33977465
pmcid: 8490495
Von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schüring AN, Bruckner T, et al. Fertility-preservation counselling and treatment for medical reasons: Data from a multinational network of over 5000 women. Reprod Biomed Online. 2015;31:605–612. https://doi.org/10.1016/j.rbmo.2015.07.013
doi: 10.1016/j.rbmo.2015.07.013
Chronopoulou E, Raperport C, Sfakianakis A, Srivastava G, Homburg R. Elective oocyte cryopreservation for age-related fertility decline. J Assist Reprod Genet. 2021;38:1177–1186. https://doi.org/10.1007/s10815-021-02072-w
doi: 10.1007/s10815-021-02072-w
pubmed: 33608838
pmcid: 7894970
Hoekman EJ, Louwe LA, Rooijers M, van der Westerlaken LAJ, Klijn NF, Pilgram GSK, et al. Ovarian tissue cryopreservation: Low usage rates and high live-birth rate after transplantation. Acta Obstet Gynecol Scand. 2020;99:213–221. https://doi.org/10.1111/aogs.13735
doi: 10.1111/aogs.13735
pubmed: 31538662
Clowse MEB, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis. J Women’s Heal. 2009;18. https://doi.org/10.1089/jwh.2008.0857
Meistrich ML, Shetty G. Hormonal suppression for fertility preservation in males and females. Reproduction. 2008;136:691–701. https://doi.org/10.1530/REP-08-0096
doi: 10.1530/REP-08-0096
pubmed: 18515310
pmcid: 2605202
Wang MY, Wang YX, Li-Ling J, Xie HQ, Adult stem cell therapy for premature ovarian failure: from bench to bedside. Tissue Eng - Part B Rev. 2022;28. https://doi.org/10.1089/ten.teb.2020.0205
Na J, Kim GJ. Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review. J Ovarian Res. 2020;13:74 https://doi.org/10.1186/s13048-020-00671-2
doi: 10.1186/s13048-020-00671-2
pubmed: 32576209
pmcid: 7313218
Tauchmanovà L, Selleri C, De Rosa G, Sammartino A, Di Carlo C, Musella T, et al. Estrogen-progestin therapy in women after stem cell transplant: Our experience and literature review. Menopause. 2007;14:320–330. https://doi.org/10.1097/01.gme.0000232032.84788.8c
doi: 10.1097/01.gme.0000232032.84788.8c
pubmed: 17108848
Spinelli S, Chiodi S, Bacigalupo A, Brasca A, Valenzano Menada M, Petti AR, et al. Ovarian recovery after total body irradiation and allogeneic bone marrow transplantation: Long-term follow up of 79 females. Bone Marrow Transpl. 1994;14:373–80.